Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Dec 8 2022 | Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes Industry News In The News Industry Read More Nov 14 2022 | Bridging the Gap: Advancing Health Equity in Heart Failure Patient News Heart Failure Awareness 365 Patient Resource Read More Nov 7 2022 | Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease Industry News In The News Industry Read More Nov 7 2022 | FARXIGA improved symptom burden and health-related quality of life in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More Nov 6 2022 | HFSA President's Update: November 2022 HFSA News President's Updates Read More Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last »
Dec 8 2022 | Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes Industry News In The News Industry Read More
Nov 14 2022 | Bridging the Gap: Advancing Health Equity in Heart Failure Patient News Heart Failure Awareness 365 Patient Resource Read More
Nov 7 2022 | Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease Industry News In The News Industry Read More
Nov 7 2022 | FARXIGA improved symptom burden and health-related quality of life in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More
